Although immunotherapeutics targeting the inhibitory receptors (IRs) CTLA-4, PD-1 or PD-
L1 have made substantial clinical progress in cancer, a considerable proportion of patients …

Evidence suggests that cancer immunotherapy will be a major part of the combination
treatment plan for many patients with many cancer types in the near future. There are many …

Despite major advancements in lung cancer treatment, long-term survival is still rare and a
deeper understanding of molecular phenotypes would allow the identification of specific …

The B7‐CD 28 family of ligands and receptors play important roles in T‐cell co‐stimulation
and co‐inhibition. Phylogenetically they can be divided into three groups. The recent …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion
of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in …

Co-inhibitory B7-CD28 family member proteins negatively regulate T cell responses and are
extensively involved in tumor immune evasion. Blockade of classical CTLA-4 (cytotoxic T …

Despite widespread utilization of immunotherapy, treating immune-cold tumors has proved
to be a challenge. Here, we report that expression of the immune checkpoint molecule B7 …

Rational modulation of the immune response with biologics represents one of the most
promising and active areas for the realization of new therapeutic strategies. In particular, the …

Immune responses must be fine‐tuned to allow effective clearance of invading pathogens,
while maintain tolerance to self‐antigens. T cells are the major effector cells for fighting and …

Purpose: The objective of this study was to evaluate clinical significance and
immunosuppressive mechanisms of B7-H4 (B7x/B7S1), a B7 family member, in glioma …